Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Purchased by EFG Asset Management Americas Corp.

EFG Asset Management Americas Corp. raised its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 42.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 10,974 shares of the medical research company’s stock after acquiring an additional 3,258 shares during the period. Thermo Fisher Scientific makes up about 1.2% of EFG Asset Management Americas Corp.’s portfolio, making the stock its 27th biggest position. EFG Asset Management Americas Corp.’s holdings in Thermo Fisher Scientific were worth $6,069,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. International Assets Investment Management LLC lifted its holdings in Thermo Fisher Scientific by 17.0% in the fourth quarter. International Assets Investment Management LLC now owns 1,902 shares of the medical research company’s stock valued at $1,010,000 after acquiring an additional 276 shares during the period. Accretive Wealth Partners LLC increased its holdings in Thermo Fisher Scientific by 8.1% in the fourth quarter. Accretive Wealth Partners LLC now owns 640 shares of the medical research company’s stock valued at $340,000 after buying an additional 48 shares in the last quarter. Aveo Capital Partners LLC boosted its position in Thermo Fisher Scientific by 9.7% during the fourth quarter. Aveo Capital Partners LLC now owns 816 shares of the medical research company’s stock worth $433,000 after purchasing an additional 72 shares in the last quarter. Gryphon Financial Partners LLC lifted its holdings in Thermo Fisher Scientific by 8.5% during the fourth quarter. Gryphon Financial Partners LLC now owns 1,484 shares of the medical research company’s stock valued at $794,000 after purchasing an additional 116 shares in the last quarter. Finally, Principal Securities Inc. purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth about $1,931,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares in the company, valued at approximately $76,420,473.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Marc N. Casper sold 6,300 shares of the business’s stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $602.09, for a total transaction of $3,793,167.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares in the company, valued at $74,548,375.44. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares in the company, valued at $76,420,473.36. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 23,084 shares of company stock worth $14,094,292. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Trading Up 0.7 %

Shares of TMO stock traded up $4.45 on Friday, hitting $611.33. The stock had a trading volume of 1,868,789 shares, compared to its average volume of 938,285. The company’s 50 day moving average price is $584.07 and its 200-day moving average price is $577.99. Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $622.30. The firm has a market capitalization of $233.35 billion, a P/E ratio of 39.21, a P/E/G ratio of 2.85 and a beta of 0.78. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.72 and a quick ratio of 1.37.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, July 24th. The medical research company reported $5.37 EPS for the quarter, beating the consensus estimate of $5.13 by $0.24. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The business had revenue of $10.54 billion during the quarter, compared to analyst estimates of $10.50 billion. During the same quarter last year, the firm posted $5.15 earnings per share. The business’s revenue for the quarter was down 1.4% compared to the same quarter last year. Analysts anticipate that Thermo Fisher Scientific Inc. will post 21.72 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Friday, September 13th will be paid a dividend of $0.39 per share. The ex-dividend date is Friday, September 13th. This represents a $1.56 annualized dividend and a yield of 0.26%. Thermo Fisher Scientific’s payout ratio is 10.01%.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on TMO. Barclays lowered their price objective on Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating on the stock in a report on Friday, June 28th. Royal Bank of Canada increased their price objective on Thermo Fisher Scientific from $660.00 to $664.00 and gave the company an “outperform” rating in a research note on Thursday, July 25th. Jefferies Financial Group reaffirmed a “buy” rating and set a $650.00 target price (up previously from $600.00) on shares of Thermo Fisher Scientific in a research note on Monday, June 3rd. Evercore ISI cut their price objective on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an “outperform” rating for the company in a report on Tuesday, July 2nd. Finally, TD Cowen boosted their price objective on Thermo Fisher Scientific from $648.00 to $658.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Four investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $630.41.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.